Expert Review of Pharmacoeconomics and Outcomes Research 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Learnings from cross-border biosimilar pricing policies in Europe
Expert Rev Pharmacoecon Outcomes Res. 2024 Mar 26:1-4. doi: 10.1080/14737167.2024.2334343. Online ahead of print.NO ABSTRACTPMID:38530083 | DOI:10.1080/14737167.2024.2334343 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - March 26, 2024 Category: Health Management Authors: Steven Simoens Teresa Barcina Lacosta Andr ás Inotai Source Type: research
Assessing the economic impact of digital endpoints on medication adherence
Expert Rev Pharmacoecon Outcomes Res. 2024 Mar 25:1-3. doi: 10.1080/14737167.2024.2334893. Online ahead of print.NO ABSTRACTPMID:38520281 | DOI:10.1080/14737167.2024.2334893 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - March 23, 2024 Category: Health Management Authors: Ahmad Z Al Meslamani Nannan Li Source Type: research
Assessing the Economic Impact of Digital endpoints on medication adherence
Expert Rev Pharmacoecon Outcomes Res. 2024 Mar 23. doi: 10.1080/14737167.2024.2334893. Online ahead of print.NO ABSTRACTPMID:38520281 | DOI:10.1080/14737167.2024.2334893 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - March 23, 2024 Category: Health Management Authors: Ahmad Z Al Meslamani Nannan Li Source Type: research
Incorporating public and wider stakeholder views in the design of health state valuation studies in adults and young people: an undervalued resource?
Expert Rev Pharmacoecon Outcomes Res. 2024 Mar 22. doi: 10.1080/14737167.2024.2334349. Online ahead of print.NO ABSTRACTPMID:38517687 | DOI:10.1080/14737167.2024.2334349 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - March 22, 2024 Category: Health Management Authors: Philip A Powell Source Type: research
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis
CONCLUSIONS: Toripalimab plus axitinib was unlikely to be the cost-effective first-line therapy for patients with previously untreated advanced RCC compared with sunitinib from the Chinese healthcare system perspective.PMID:38506058 | DOI:10.1080/14737167.2024.2333334 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - March 20, 2024 Category: Health Management Authors: Shuo Kang Jintuo Yin Source Type: research
